Literature DB >> 23264243

Echocardiographic changes after cardiac resynchronisation therapy.

Rudolf Praus1, Ludek Haman, Miloslav Tauchman, Radek Pudil, Vaclav Blaha, Petr Parizek.   

Abstract

BACKGROUND AND AIM: The aim of this prospective study was to evaluate echocardiographic changes in clinical responders and nonresponders after 3 and 15 months of cardiac resynchronisation therapy (CRT).
METHODS: Fifty eight patients in whom a biventricular system was implanted between 2005 and 2008 were followed up at 3 and at 15 months. Clinical and echocardiography parameters including intra- and interventricular dyssynchrony were assessed at baseline and after 3 and 15 months of CRT. Every patient in whom quality of life, New York Heart Association (NYHA) class and/or 6-minute walk test (6MWT) improved (improvement of ≥ 1 NYHA class, 6MWT by more than 10%), and who was neither in hospital for heart failure nor died for cardiac reasons, was categorised as a clinical responder.
RESULTS: In the responders' group, we found a significant improvement of right ventricular systolic function and a decrease in the size of the right ventricle (RV) only after 15 months (tricuspid annular plane systolic excursion [TAPSE] 17.8 ± 4.0 mm to 19.4 ± 3.7 mm, p 〈 0.05, RV diameter 29.3 ± 5.0 mm to 27.8 ± 4.2 mm, p 〈 0.05). Significant improvement of other monitored parameters occurred 3 months after CRT implantation: left ventricle (LV) end-diastolic diameter 70.5 ± 7.8 mm to 66.1 ± 8.3 mm, p 〈 0.001, LV ejection fraction 22.0 ± 5.4% to 27.1 ± 9.8%, p 〈 0.05, pulmonary artery pressure (peak gradient of tricuspid regurgitation) 37.1 ± 14.8 mm Hg to 27.6 ± 8.9 mm Hg, p 〈 0.001, tricuspid regurgitation (grade) 1.9 ± 0.9 to 1.5 ± 0.6, p 〈 0.05, mitral regurgitation (grade) 2.6 ± 0.9 to 2.2 ± 0.9, p 〈 0.001, LV dP/dt max (peak positive rate of pressure rise [slope of mitral regurgitant jet]) 482.4 ± 155.4 mm Hg/s to 981.2 ± 654.5 mm Hg/s, p 〈 0.001, velocity time integral (VTI) in LV outflow tract (LVOT) 14.1 ± 4.3 cm to 16.7 ± 4.1 cm, p 〈 0.001. In the group of nonresponders, only 2 parameters improved significantly: LV dP/dt max 561.2 ± 347.9 mm Hg/s to 1024.5 ± 745.3 mm Hg/s, p 〈 0.001, and LVOT VTI 14.5 ± 3.0 cm to 16.3 ± 2.9 cm, p 〈 0.001. Other echocardiographic parameters did not show any important changes, and no changes occurred between 3 and 15 months. On the contrary, after 15 months we saw significant progression of tricuspid regurgitation in nonresponders. In multivariate analysis, combination of baseline delay between time to peak systolic velocity in ejection phase at basal septal and basal lateral segments (Ts-lateral-septal delay) and serum creatinine was a strong predictor of clinical CRT response (area under curve was 0.80, percentage of correct decision was 82%).
CONCLUSIONS: In the group of responders, significant changes of most monitored echocardiographic parameters were observed 3 months after CRT implantation. The only parameters which changed significantly after 15 months, but not previously, were the systolic function of the RV and the decrease in the RV size. In the group of nonresponders, these changes were not observed.

Entities:  

Mesh:

Year:  2012        PMID: 23264243

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  3 in total

Review 1.  Changes in parameters of right ventricular function with cardiac resynchronization therapy.

Authors:  Abhishek Sharma; Carl J Lavie; Ajay Vallakati; Akash Garg; Sunny Goel; Jason Lazar; Gregg C Fonarow
Journal:  Clin Cardiol       Date:  2017-09-12       Impact factor: 2.882

2.  Comparison of Tricuspid Regurgitation Severity Between Cardiac Resynchronization Therapy Versus Right Ventricular Pacing in Patients With Chronic Obstructive Pulmonary Disease.

Authors:  James Livesay; Benjamin Fogelson; Hassan Tahir; Raj Baljepally
Journal:  Cardiol Res       Date:  2022-06-16

3.  Development and Validation of Predictive Models of Cardiac Mortality and Transplantation in Resynchronization Therapy.

Authors:  Eduardo Arrais Rocha; Francisca Tatiana Moreira Pereira; José Sebastião Abreu; José Wellington O Lima; Marcelo de Paula Martins Monteiro; Almino Cavalcante Rocha Neto; Camilla Viana Arrais Goés; Ana Gardênia P Farias; Carlos Roberto Martins Rodrigues Sobrinho; Ana Rosa Pinto Quidute; Maurício Ibrahim Scanavacca
Journal:  Arq Bras Cardiol       Date:  2015-08-07       Impact factor: 2.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.